- A study presented at a recent meeting in Cambridge, UK, on hemophilia therapy has suggested that the use of implantable intravenous access devices may be applicable as a prophylactic measure for children with the disorder whose veins are small and difficult to access. In the trial, the devices were used for a mean of 35 months and were still in place in 10 of the study's 11 patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze